ARCpoint

ARCpoint EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ARCpoint (ARC.V) as of Oct 24, 2026 is -2.57 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -3.21 M USD — a change of -19.81% (higher).

EBITDA

-2.57 MUSD

YoY

-19.81%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ARCpoint is 2025 -2.57 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ARCpoint was 2024 -3.21 M USD. It decreases by -19.81% higher compared to the previous year.

The ARCpoint EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2021
5.91 M USD
Jan 1, 2022
-3.60 M USD
Jan 1, 2023
-6.85 M USD
Jan 1, 2024
-3.21 M USD
Jan 1, 2025
-2.57 M USD
The ARCpoint EBITDA history
YEAREBITDAYoY
-2.57 MUSD-19.81%
-3.21 MUSD-53.18%
-6.85 MUSD+90.19%
-3.60 MUSD-160.95%
5.91 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ARCpoint Stock analysis

What does ARCpoint do? ARCpoint, Inc. generates revenue through its franchise system, which includes drug testing, alcohol screening, DNA, and clinical lab testing services. The ARCpoint Franchise segment sells franchises to individuals across the United States, providing marketing, technology, and training support. The AFG Services segment offers clinical testing, software services, and diagnostic testing kits to franchisees and other business-to-business customers. The Other segment operates corporate-owned labs that serve businesses, physicians, and customers directly. Revenue streams include franchise fees, sales of diagnostic kits, and corporate lab services. ARCpoint Franchise segment revenue comes from franchise sales and ongoing support services. AFG Services segment revenue is derived from clinical testing, software services, and direct sales of diagnostic kits to business customers. Corporate-owned labs in the Other segment provide clinical and diagnostic services to businesses, physicians, and end customers, contributing to overall revenue. The company's business model relies on a mix of franchise sales, service offerings, and direct B2B transactions. The company's primary customers are individuals purchasing franchises, businesses requiring clinical testing, and physicians seeking diagnostic services. Franchisees benefit from ARCpoint's marketing, technology, and training support. AFG Services targets businesses needing diagnostic kits and software solutions. Corporate-owned labs serve businesses, physicians, and end customers with comprehensive testing solutions. Revenue is generated through multiple channels within the company's segmented structure. ARCpoint is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ARCpoint stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ARCpoint is -2.57 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ARCpoint changed from -3.21 M USD to -2.57 M USD, representing a -19.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) ARCpoint since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s ARCpoint historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — ARCpoint

All Key Metrics — ARCpoint